A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Trial of S-4321 in Healthy Volunteers
Latest Information Update: 20 Mar 2025
At a glance
- Drugs S-4321 (Primary) ; S-4321 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Seismic Bio
- 14 Mar 2025 Status changed from planning to not yet recruiting.
- 18 Nov 2024 According to a Seismic Therapeutic media release, company plans to initiate a Phase 1 clinical trial of S-4321 in healthy volunteers in the first half of 2025.
- 08 Dec 2023 New trial record